Welcome to the Reed Lab web page. Here you will find information about the research carried out in the group and links to useful resources.
Basic biomedical research in the Reed group has focused on determining the mechanism of NER for many years (see Simon Reed's time line). The group has developed a number of in vitro and in vivo DNA repair assays including a novel technology that enables the measurement of DNA damage and its rates of repair at high resolution throughout whole genomes. This technique, which is based on a modified version of the ChIP on Chip method, was originally developed for examining DNA damage and repair events in yeast cells to examine the mechanism of NER. This technology has a range of industrial and translational applications, and is patented (US Patent No 8518641, BPA 0922248.0). We undertook a Knowledge Transfer Partnership with Agilent Technologies, whose microarray platform we employ, to develop the method for use in human cells. The technology is now available as an Agilent Application Note. We are currently collaborating with GSK and Unilever to evaluate the technology for its use in genotoxicity testing. We are also developing the method for clinical applications where the aim is to identify platinum-induced DNA damage/repair signatures that are predictive of an individual's response to platinum-based chemotherapy.
Our research has underpinned the development of novel genomic methods for measuring DNA damage and repair in chromatin using microarray- and next generation sequencing-based technologies. In addition to the laboratory-based techniques, we have also developed important bioinformatic tools for analyzing the datasets generated from these genomic experiments (Bennett et al. 2015 and Sandcastle). We have established the core technologies required in both yeast and human cells, and set out a framework for understanding how DNA damage is removed from chromatin by NER on a genome-wide scale.